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In the present study, it was demonstrated that the sensitivity of the PCR for the detection of Chlamydia
trachomatis is influenced by the volume of the clinical sample which is processed in the PCR. An adequate
sensitivity for PCR was established by processing at least 4%, i.e., 80 ml, of the clinical sample volume per PCR.
By using this preparation procedure, 1,110 clinical samples were evaluated by PCR and by cell culture, and
results were compared. After discordant analysis, cell culture resulted in a sensitivity of 79.1% and PCR
resulted in a sensitivity of 92.7%. Furthermore, it was shown that treatment with antibiotics immediately
resulted in negative cell culture results but that PCR could give positive results up to 2 weeks posttreatment.
The PCR technique has become an important tool for the
diagnosis of Chlamydia trachomatis urogenital infections (1,
2, 4, 6, 10, 11). Most laboratories use rather labor-intensive
procedures for the isolation and concentration of target DNA
in urogenital specimens (2). The phenol extraction method has
a concentrating effect as well as a purifying effect. Sample
volumes of 1 ml or more can easily be concentrated to 100 ml,
and of this concentrated DNA, a predetermined volume is
added to the PCR mixture. Claas et al. (2, 3) applied 100 ml of
an initial sample volume to a final PCR analysis. By making use
of this procedure, they established a PCR sensitivity of 100%
and a specificity of 98.5% compared with Chlamydia cell
culture (CC). In the investigative study of Kluytmans et al. (7),
a modified DNA extraction procedure which was more suitable
for processing large numbers of specimens was used. Although
specificity values for both males and females were high (99.6
and 99.9%, respectively), sensitivities were low. Furthermore,
the overall sensitivity correlated with the number of infectious,
inclusion-forming elementary bodies (EBs), as determined by
CC, indicating that this PCR assay was hampered by the
presence of a limited number of DNA targets in the patient
sample. In fact, only 2.2 ml of the initial sample volume was
processed in the final PCR.
The present report describes the optimization of a sample
preparation procedure suitable for processing large numbers
of specimens and compares its clinical performance with that
of CC with regard to the detection of C. trachomatis in
urogenital specimens. Specimens were collected from 1,110
patients visiting the outpatient clinic for sexually transmitted
diseases at the University Hospital of Rotterdam. Male ure-
thral samples and female cervical samples were collected from
patients who were clinically suspected of having C. trachomatis
infections. Sample collection was performed by using a Dacron
E.N.T. swab (Medical Wire and Equipment Co., Corsham,
Willshire, United Kingdom), which was placed into 2 ml of 0.2
M sucrose phosphate buffer. Processing and CC procedures for
the samples were performed as described previously (7). In
order to determine the influence of sample preparation pro-
cedures on the sensitivity of the PCR, different DNA isolation
procedures were performed on clinical samples categorized
according to the number of infectious EBs present in the CC
sample. The number of infectious EBs per patient sample was
quantitated by microscopic determination of the number of
inclusion bodies per 400-ml sample of specimen in a McCoy
cell monolayer (7). Samples containing 1 to 5, 6 to 20, and
more than 20 EBs per 400-ml sample volume were designated
to contain small, intermediate, and large numbers of C.
trachomatis organisms, respectively. Twenty samples from each
category were tested. The following four procedures were
evaluated.
Method a. For method a, a 200-ml sample of specimen was
centrifuged for 10 min at 14,0003 g at room temperature. The
pellet was resuspended in 75 ml of phosphate-buffered saline.
Sixty microliters of this suspension was incubated with 10 ml of
proteinase K (2.5 mg) and 10 ml of 6% Triton X-100 for 1 h at
378C. After the solution was heated to 1008C for 10 min to
inactivate the proteinase K, 100 ml of sterile water (distilled
twice) was added to the sample. Ten microliters of this solution
was subsequently added to 90 ml of PCR mixture.
Method b. For method b, a 30-ml sample of specimen was
treated with 5 ml of proteinase K (1.25 mg) and 5 ml of 6%
Triton X-100, incubated for 1 h at 378C, boiled for 10 min, and
added as a whole to 60 ml of PCR mixture.
Method c. For method c, a 200-ml sample of specimen was
treated with 30 ml of proteinase K (7.5 mg) and 30 ml of 6%
Triton X-100, incubated for 1 h at 378C, and subsequently
boiled for 10 min. From each lysate, 30 ml was added to 70 ml
of PCR mixture.
Method d. For method d, a 400-ml sample of specimen was
centrifuged for 30 min at 14,0003 g, and the pellet was treated
with 40 ml of lysis buffer (50 mM Tris-HCl [pH 7.5], 1% Triton
X-100, 1 mM EDTA, 250 mg of proteinase K per ml). After
incubation at 378C for 1 h, the lysates were boiled for 10 min
and centrifuged briefly. From each lysate, 8 ml was added to 92
ml of PCR mixture. Method d is a modification of a method
described initially by Ossewaarde et al. (9), and this method
was applied in the clinical evaluation of 1,110 consecutive
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patient samples. Primers and PCR conditions were the same as
those described in the paper of Kluytmans et al. (7). Discor-
dant results were analyzed by a confirmatory PCR using
primers recognizing the gene coding for major outer mem-
brane proteins (MOMPs) (13).
The rationale for the four procedures selected is that they
permit the addition of increasing initial sample volumes to the
PCR without changing the method of sample processing
significantly. If the dilution factors are taken into account, the
actual clinical sample volumes processed in methods a, b, c,
and d were 2.2, 30, 27, and 80 ml, representing 0.11, 1.5, 1.35,
and 4% of the original 2-ml clinical sample volume, respec-
tively. Another aspect of the four methods described that we
studied was the time at which the lysis step took place, i.e.,
before (methods c and d) or after (methods a and b) the final
subsample was taken for use in the PCR.
Table 1 shows the results obtained by application of the four
different sample preparation procedures to clinical samples
categorized according to the numbers of EBs they contained,
as determined by CC. Assays of the 20 clinical samples
containing large numbers of EBs showed that PCR using
sample treatment procedure c or d resulted in a 100% concor-
dance with CC results. Differences in sensitivity obtained, for
instance, by methods b and c were statistically significant
(Fisher exact test, P5 0.001). These differences are striking, as
the same sample volume is applied in the final PCR in each
method. This difference can be explained by the fact that in
method c, 200 ml of the specimen is lysed as a whole before the
sample for the final PCR is taken. In contrast, in method b the
final PCR sample is taken before the lysis step. It is thus
conceivable that lysis before sampling increases the chance of
catching DNA available for amplification because of the
release of multicopy plasmid DNA. In the case of clinical
samples containing intermediate numbers of EBs, the differ-
ence in performance between methods b and c was still
apparent; however, it was statistically not significant (P 5
0.527). Analysis of the intermediate samples showed that
method c missed 9 of the 20 samples. Method d, on the other
hand, detected 20 of 20 samples, indicating that optimal
sensitivity can only be reached by concentrating the original
sample specimen. However, samples containing small numbers
of EBs showed that even method d had a sensitivity limited to
75%. This limited sensitivity may have been due to sampling
error, since we were dealing with samples containing less than
five EBs per 400 ml of patient specimen. Statistically, only one
EB or less was present in a volume of 80 ml, which was the final
specimen volume applied in method d. On the basis of data
obtained with samples containing large numbers of EBs and
samples containing intermediate numbers of EBs, we con-
cluded that method d constitutes the best sample treatment
procedure. Method a, as applied in the study of Kluytmans et
al. (7), proved to be the least sensitive procedure. In this
protocol, the DNA was not purified and it was actually diluted
instead of being concentrated. If the dilution factor is taken
into account, only 2.2 ml of the original 200-ml sample of
specimen (i.e., 0.11%) was used in the PCR assay.
A prospective clinical evaluation was subsequently per-
formed on 1,110 samples by using method d. Table 2 shows the
results of this evaluation. If the CC results only are used as a
‘‘gold standard,’’ the sensitivity and specificity of PCR were
90.8% and 96.8%, respectively. Of the 1,023 CC-negative
samples, 33 were PCR positive. The results showed C. tracho-
matis prevalences to be 7.8% as determined by culture and
10.1% as determined by PCR. Eight culture-positive samples
were missed by PCR.
To gain insight into the relation between the number of EBs
in the culture-positive samples and PCR results, the samples
were categorized into the predefined categories described
above. In Table 3 it can be seen that six of the eight samples
missed by PCR (i.e., 75%) contained fewer than five EBs per
400-ml sample of specimen. Of these six samples, four were
available, and results obtained with them could be confirmed
by PCR conducted on extracts of the corresponding CCs (data
not shown). The remaining two CC-positive samples missed by
PCR were in the intermediate- and large-number categories.
Discrepancy analysis of these two samples performed by using
a primer set aimed at the MOMP gene revealed that the
intermediate-number category sample probably stayed nega-
tive because of inhibitory substances in the concentrated
sample. The large-number category sample initially missed was
positive with the MOMP primer set.
Furthermore, a discrepancy analysis was performed on the
33 PCR-positive, CC-negative samples by using the same
TABLE 1. Sensitivities of different sample preparation procedures
with clinical specimens containing small, intermediate,
and large numbers of EBs in CC
Sample preparation procedure
Sensitivity (%) of PCR with samples
containing the following no.
of EBs in CCa:
Small Intermediateb Largec
a 40 30 70
b 65 40 55
c NDd 55 100
d 75 100 100
a Twenty samples from each category were evaluated.
b Statistically significant differences (Fisher exact test) exist between results for
methods a and d (P , 0.001), b and d (P , 0.001), and c and d (P , 0.001).
c Significant differences exist between results for methods a and c (P 5 0.020),
a and d (P 5 0.020), b and c (P 5 0.001), and b and d (P 5 0.001).
d ND, Not Determined.
TABLE 2. Results of CC and PCR for 1,110 clinical samples,
obtained by using sample preparation method d
Result by
PCRa
No. of samples with the
following result by CC: Total
1 2
1 79 33 112
2 8 990 998
Total 87 1,023 1,110
a The performance of PCR compared with that of CC was as follows:
sensitivity, 90.8%; specificity, 96.8%; positive predictive value, 70.5%; and
negative predictive value, 99.2%.
TABLE 3. Culture-positive samples categorized according to
numbers of EBs
No. of EBsa No. of samples No. of PCR-positivesamples
No. of PCR-negative
samplesb
Small 20 14 6 (70.0%)
Intermediate 17 16 1 (94%)
Large 50 49 1 (98.0%)
Total 87 79 8 (90.8%)
a Numbers of EBs determined to be present in 400-ml samples of specimen.
b The sensitivity of PCR is denoted in parentheses.
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MOMP primer set. In this group, 23 of 33 samples were
positive by the MOMP PCR. It should be realized that the
MOMP gene is a single-copy gene and that this assay may,
therefore, be less sensitive than a PCR procedure which targets
the endogenous multicopy plasmid. In a paper of Ossewaarde
et al. (9) it was demonstrated that a PCR performed with a
MOMP primer set, on a twofold dilution of a serovar suspen-
sion, was fourfold less sensitive than a PCR performed with a
plasmid primer set.
To help explain PCR-positive, CC-negative results, the
medical records of the patients involved were analyzed for
antibiotic treatment during the week preceding the time of
sampling. Nine of the 33 (27.3%) PCR-positive, CC-negative
patients had been treated. Seven of the nine samples from
these patients were also positive in the PCR performed with
the MOMP primer set. From four patients we received pre-
treatment samples and posttreatment follow-up samples, and it
was observed that at 1 to 3 weeks after initiation of antibiotic
treatment CCs were negative and PCR results were still
positive. At 3 weeks posttreatment samples were PCR and CC
negative for all patients. These results are in accordance with
the findings of other authors (8, 12). The remaining 24 of the
33 PCR-positive, CC-negative patients had not received anti-
biotics, but each was screened for a C. trachomatis infection,
since all patients were determined to be at risk on the basis of
clinical and/or epidemiological criteria. After analysis of dis-
cordant results by MOMP PCR, the sensitivity and specificity
of both CC and PCR were recalculated by defining another
gold standard. The assumption that if CC was negative but
PCR was positive with both primer sets a failure of CC had
occurred was made. In addition to the 87 CC-positive samples,
PCR detected 23 other true-positive samples. This adds up to
110 true-positive samples and 1,000 true-negative samples. CC
detected 87 and PCR detected 102 of the 110 true-positive
samples, resulting in sensitivity values of 79.1 and 92.7%,
respectively. Because analysis of CC-positive, PCR-negative
specimens was not performed, the specificity of CC was 100%
by definition. The recalculated specificity of PCR was 99.0%.
On the basis of these data we conclude that even with PCR,
a minimal volume of clinical sample (i.e., at least 4%) has to be
processed to obtain an adequately sensitive assay. A few
samples containing small numbers of EBs are missed. These
latter findings are in accordance with the results of Roosendaal
et al. (12) and Gilroy et al. (5), who also demonstrated that
when cervical smears contain small numbers of EBs (,10
EBs), PCR can produce negative results.
One of the problems with the current PCR techniques for
detecting C. trachomatis is that with the sample processing
methods available, the ratio of target DNA to aspecific DNA
and inhibitory substances present in the processed sample is in
favor of the latter two substances. Future diagnostic assays
should be designed in such a way that in the sample processing
procedure, only target DNA or RNA is isolated (captured)
from large volumes of patient specimens and is added in total
to the PCR assay. If this strategy is followed, the sensitivity of
the assay will likely increase and the problems associated with
false-negative results due to inhibitory substances will be
circumvented. However, even without the use of sophisticated
sample processing techniques we also demonstrated that the
currently applied PCR detects additional positive patients,
most of whom are truly positive for C. trachomatis infection.
However, the clinical relevance of PCR-positive, CC-negative
results, especially in relation to antibiotic treatment, has to be
established in further studies.
(Part of this research has been presented at the 94th General
Meeting of the American Society for Microbiology in Las
Vegas, Nev. [22 to 27 May 1994]. The abstract number was
C-452.)
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